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ORIGINAL ARTICLE
Efficacy and Safety of Subcutaneous Golimumab
in Methotrexate-Naive Patients With Rheumatoid
Arthritis: Five-Year Results of a Randomized
Clinical Trial
PAUL EMERY,1 ROY M. FLEISCHMANN,2 INGRID STRUSBERG,3 PATRICK DUREZ,4 PETER NASH,5
ERIC JASON B. AMANTE,6 MELVIN CHURCHILL,7 WON PARK,8 BERNARDO PONS-ESTEL,9
CHENGLONG HAN,10 TIMOTHY A. GATHANY,10 STEPHEN XU,11 YIYING ZHOU,11
JOCELYN H. LEU,11 AND ELIZABETH C. HSIA12
Objective. To evaluate the safety and efficacy of golimumab through 5 years in adults with active rheumatoid arthritis
(RA) who had not previously received methotrexate (MTX).
Methods. In the GO-BEFORE study, 637 MTX-naive adult patients with active RA were randomized (1:1:1:1) to pla-
cebo1MTX (group 1), golimumab 100 mg1placebo (group 2), golimumab 50 mg1MTX (group 3), or golimumab
100 mg1MTX (group 4). Inadequate responders in groups 1, 2, and 3 entered early escape at week 28 to golimumab
50 mg1MTX, golimumab 100 mg1MTX, or golimumab 100 mg1MTX, respectively; remaining patients in group 1 could
cross over to golimumab 50 mg1MTX at week 52. Assessments included the American College of Rheumatology 20%/50%/
70% improvement criteria (ACR20/50/70) response, the Disease Activity Score in 28 joints (DAS28) using C-reactive protein
(CRP) level, and the modified Sharp/van der Heijde score (SHS). Efficacy was analyzed using an intent-to-treat (ITT) analysis.
Pharmacokinetics and immunogenicity were evaluated at selected visits.
Results. A total of 422 patients completed golimumab treatment through week 256. At week 256, 72.8%, 54.6%, and
38.0% of all patients in the full ITT population (n5 637) had an ACR20/50/70 response, respectively; 84.1% had a
good or moderate DAS28-CRP response; and 72.7% had a clinically meaningful improvement in physical function.
Radiographic progression was minimal in all treatment groups through week 256, and the overall mean change from
baseline in SHS was 1.36. Serum trough golimumab concentrations were approximately dose proportional and main-
tained through week 256. Antibodies to golimumab occurred in 9.6% of patients through week 256. Infections were
the most common type of adverse event (AE); 204 of 616 patients (33.1%) had ‡1 serious AE.
Conclusion. Clinical efficacy with golimumab treatment was maintained through week 256 of the GO-BEFORE trial of
MTX-naive RA patients. No unexpected AEs occurred; safety results through 5 years are consistent with earlier reports.
INTRODUCTION
Golimumab, a fully human anti–tumor necrosis factor
(TNF) antibody, has been shown to improve the signs and
symptoms of rheumatoid arthritis (RA) in adults in large,
randomized, placebo-controlled phase 3 trials (1–3). The
GO-BEFORE trial evaluated the safety and efficacy of sub-
cutaneous (SC) golimumab in adult patients with RA who
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had not previously received methotrexate (MTX) therapy,
and results through 2 years have been reported (1,4). In the
GO-BEFORE trial, patients treated with golimumab (50 mg
or 100 mg)1MTX had significantly greater improvements
in the signs and symptoms of RA than those treated with
MTX monotherapy. These improvements were observed at
week 24 (1) and were maintained through 2 years (4). In
addition, golimumab1MTX-treated patients had signifi-
cantly less radiographic progression through 1 year when
compared with those who received MTX monotherapy (5).
Here we report the final efficacy and safety results of the
GO-BEFORE trial through 5 years.
PATIENTS AND METHODS
Patients and study design. The detailed eligibility crite-
ria and study design of the GO-BEFORE trial have been pre-
viously described (1). Briefly, adult patients with active RA
who had not been previously treated with MTX were ran-
domly assigned to receive SC injections of placebo1MTX
(group 1), golimumab 100 mg1placebo (group 2), golimu-
mab 50 mg1MTX (group 3), or golimumab 100 mg1MTX
(group 4); injections were administered at baseline and every
4 weeks. Active RA was defined as $4 swollen joints, $4
tender joints, and at least 2 of the following criteria: C-
reactive protein (CRP) level of$1.5 mg/dl or erythrocyte sed-
imentation rate$28 mm/hour using the Westergren method;
morning stiffness lasting $30 minutes; or evidence of bone
erosion radiographs or magnetic resonance imaging (1). Eligi-
ble patients also could not have a history of latent tuberculo-
sis (TB) prior to screening and could not have any signs or
symptoms of active TB. Patients were screened for TB by
chest radiographs (both posteroanterior and lateral views)
within 3 months before the first study drug administration
and diagnostic testing (tuberculin and QuantiFERON-TB
Gold tests) within 6 weeks before the first study drug admin-
istration. Patients with a newly identified positive result
(tuberculin or QuantiFERON-TB Gold testing) could partici-
pate in the trial if they initiated appropriate treatment for
latent TB.
Patients were stratified by investigational site and baseline
CRP level (,1.5 mg/dl or $1.5 mg/dl). Placebo and golimu-
mab injections were administered at baseline and every 4
weeks. At week 28, patients in groups 1–3 with an inadequate
response to treatment entered blinded early escape such that
patients in group 1 switched from placebo to golimumab
50-mg injections, patients in group 2 initiated concomitant
MTX therapy while continuing golimumab 100-mg injections,
and patients in group 3 increased their golimumab dose to
100 mg; patients in groups 1 and 3 continued concomitant
MTX. Patients in group 4 did not have any changes in treat-
ment regimen, regardless of their early escape status. The
active-control period continued through week 52.
The long-term extension began with the week-52 visit
and continued through week 268 (5 years). At week 52,
patients in group 1 who did not have any swollen or tender
joints continued MTX monotherapy; patients with at least 1
swollen or tender joint were switched from placebo injec-
tions to golimumab 50 mg. Patients in groups 2, 3, and 4
continued the treatment they were receiving at week 52.
The blind was maintained until the week-52 database was
locked, after which treatment adjustments could be made at
the investigator’s discretion. Patients in group 1 who were
receiving MTX monotherapy could initiate treatment with
golimumab 50 mg, and a 1-time golimumab dose increase to
100 mg or decrease to 50 mg was permitted (including
patients who had dose-escalated to 100 mg). Additionally,
MTX therapy could be initiated or adjusted during the long-
term extension period. Concomitant therapy with nonste-
roidal antirheumatic drugs (NSAIDs), corticosteroids, or
other analgesics for RA could also be adjusted at the investi-
gator’s discretion. The final study golimumab injection was
at week 252. After week 256, patients transitioned to
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standard-of-care treatment for RA, including commercially
available biologic agents.
The GO-BEFORE trial was conducted according to the
Declaration of Helsinki. The protocol was approved by the
institutional review board or ethics committee at each
site, and all patients gave written informed consent before
any study-related procedures were performed.
Evaluations. During the long-term extension, clinical
response was assessed every 12 weeks through week 256,
with an additional assessment at week 104. Disease activi-
ty was assessed using the American College of Rheumatol-
ogy (ACR) criteria (6) and the European League Against
Rheumatism Disease Activity Score in 28 joints (DAS28)
using CRP level (7). Post hoc efficacy assessments includ-
ed the Simplified Disease Activity Index (SDAI) (8) and
the Clinical Disease Activity Index (CDAI) (9).
Physical function was evaluated using the Health Assess-
ment Questionnaire (HAQ) disability index (DI) (10). Nor-
mal physical function was defined as a HAQ DI score #0.5,
and a minimal clinically important difference (MCID) was
defined as an improvement$0.25 (11). Health-related quali-
ty of life was evaluated using the physical component sum-
mary (PCS) and mental component summary (MCS) scores
of the Short Form 36-item (SF-36) health survey (12). The
impact of disease on productivity was assessed using a visu-
al analog scale (0–10 cm) at baseline and at week 256.
Radiographs of the hands and feet were obtained at weeks
52, 104, 208, and 256 during the long-term extension; results
through week 104 have been previously reported (1,4). Data
from patients with radiographs at baseline, week 104, and at
least 1 radiograph after week 104 were included in the cur-
rent analysis. As previously detailed (5), radiographs were
scored by 2 independent readers and an adjudicator using
the modified Sharp/van der Heijde score (SHS) (13).
Patients were monitored through week 268 for adverse
events (AEs). Routine laboratory analyses were performed
through week 256. The incidence of each AE was summa-
rized according to actual treatment received at the time of
the event. Blood samples were collected (prior to adminis-
tration of study agents) at selected visits for the analysis of
pharmacokinetics and evaluation for the presence of anti-
bodies to golimumab using validated immunoassays (14).
Statistical analysis. Descriptive statistics (e.g., counts and
percentages and means/medians) were used to summarize the
efficacy results of the long-term extension by randomized
treatment group. In the a priori analysis of clinical efficacy
end points (ACR components and DAS28-CRP), observed
data were used through week 256 with no imputation for
missing values. A more stringent post hoc intent-to-treat (ITT)
analysis including all randomized patients was performed on
the clinical efficacy measures, and these results are reported
herein. This ITT analysis used the following data imputation
and treatment failure rules: 1) missing baseline values for con-
tinuous variables were replaced with the median value of the
corresponding baseline CRP level stratum (,1.5 mg/dl or
$1.5 mg/dl), and the last observation carried forward (LOCF)
methodology was applied to missing postbaseline values, and
2) patients who discontinued the study agent due to unsatis-
factory therapeutic effect were imputed as nonresponders.
The proportions of patients achieving at least a 20%, 50%, or
70% improvement in the ACR criteria (ACR20/50/70
response) (6), a moderate or good DAS28-CRP response (7,15),
a DAS28-CRP,2.6, a DAS28-CRP#3.2, an MCID in HAQ DI
score, and a HAQ DI score#0.5 were determined. SF-36 and
productivity outcomes were analyzed using observed data,
with no missing data imputation, and included improvements
from baseline in SF-36 PCS and MCS scores and the impact of
disease on productivity at week 256, as well as the proportions
of patients with normal SF-36 PCS or MCS scores (score$50).
In the post hoc analysis, the proportions of patients who
achieved remission, as defined by an SDAI score #3.3 (16), a
CDAI score #2.8 (16), or Boolean definition (17) were also
determined.
Radiographic data through week 256 were summarized by
randomized treatment group and included all patients who
had radiographs at weeks 0, 104, and at least 1 radiograph
Table 1. Patients who discontinued study agent through week 252*
Golimumab1MTX
Placebo1
MTX
Golimumab
100 mg1
placebo 50 mg 100 mg Combined Total
Patients randomized, no. 160 159 159 159 318 637
Patients treated, no. 160 157 158 159 317 634
Patients who discontinued study agent 50 (31.3) 56 (35.7) 49 (31.0) 60 (37.7) 109 (34.4) 215 (33.9)
Reason for discontinuation
Initiated protocol-prohibited
medication(s)
0 0 0 0 0 0
Adverse event 21 (13.1) 32 (20.4) 24 (15.2) 34 (21.4) 58 (18.3) 111 (17.5)
Worsening of RA 0 3 (1.9) 0 1 (0.6) 1 (0.3) 4 (0.6)
Unsatisfactory therapeutic effect 5 (3.1) 6 (3.8) 5 (3.2) 7 (4.4) 12 (3.8) 23 (3.6)
Lost to followup 3 (1.9) 4 (2.5) 7 (4.4) 6 (3.8) 13 (4.1) 20 (3.2)
Death 0 3 (1.9) 3 (1.9) 2 (1.3) 5 (1.6) 8 (1.3)
Other 21 (13.1) 11 (7.0) 10 (6.3) 11 (6.9) 21 (6.6) 53 (8.4)
* Values are the number (percentage) unless indicated otherwise. MTX5methotrexate; RA5 rheumatoid arthritis.
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after week 104. Changes from baseline to week 208 and
week 256 in the SHS are reported; missing postbaseline val-
ues were replaced using the LOCF methodology. Among
patients with an SHS score at baseline and week 256, annual
rates of progression at baseline and 5 years were determined
using the SHS score divided by RA duration for each patient
at baseline and the change in SHS over 5 years.
Cumulative safety data are reported for all patients who
received at least 1 administration of golimumab through
week 268. AEs and serious AEs were summarized accord-
ing to the treatment received at the time of the event. As a
result of early escape, placebo crossover, and golimumab
dose adjustments allowed during the long-term extension,
patients could be included in more than 1 treatment
group. AEs were summarized through week 268, with the
exception of those that occurred after receipt of any com-
mercial biologic agent (including commercial golimumab).
Patients who received commercially available biologic
treatment after discontinuing study golimumab, yet who
remained in the study, had AEs reported through week
268, but these AEs were excluded from the safety summa-
ries. The rates per 100 patient-years and 95% confidence
intervals (95% CIs) for the total numbers of serious in-
fections, malignancies (including nonmelanoma skin
cancers), and death are also reported. In addition, stan-
dardized incidence ratios (SIRs) for malignancies were
determined using the Surveillance, Epidemiology and
End Results (SEER) database; nonmelanoma skin cancers
were excluded from this comparison because they are not
reported in the SEER database.
Table 2. Clinical efficacy, patient-reported outcomes, and radiographic results at week 256 using the ITT analysis*
Golimumab1MTX
Placebo1
MTX
Golimumab
100 mg1
placebo 50 mg 100 mg Combined Total
Clinical efficacy†
Patients randomized, no. 160 159 159 159 318 637
ACR20 109 (68.1) 117 (73.6) 114 (71.7) 124 (78.0) 238 (74.8) 464 (72.8)
ACR50 80 (50.0) 83 (52.2) 88 (55.3) 97 (61.0) 185 (58.2) 348 (54.6)
ACR70 61 (38.1) 59 (37.1) 57 (35.8) 65 (40.9) 122 (38.4) 242 (38.0)
DAS28-CRP response‡ 128 (80.0) 138 (86.8) 131 (82.4) 139 (87.4) 270 (84.9) 536 (84.1)
DAS28-CRP ,2.6 67 (41.9) 65 (40.9) 70 (44.0) 74 (46.5) 144 (45.3) 276 (43.3)
DAS28-CRP #3.2 86 (53.8) 90 (56.6) 91 (57.2) 94 (59.1) 185 (58.2) 361 (56.7)
SDAI #3.3 47 (29.4) 40 (25.2) 42 (26.4) 46 (28.9) 88 (27.7) 175 (27.5)
CDAI #2.8 51 (31.9) 40 (25.2) 44 (27.7) 49 (30.8) 93 (29.2) 184 (28.9)
Boolean remission 30 (18.8) 32 (20.1) 38 (23.9) 35 (22.0) 73 (23.0) 135 (21.2)
Improvement from baseline
in HAQ DI, mean6SD
0.6860.69 0.706 0.74 0.656 0.70 0.806 0.72 0.726 0.71 0.7060.71
Patients with improvement
in HAQ DI $0.25
120 (75.0) 111 (69.8) 110 (69.2) 122 (76.7) 232 (73.0) 463 (72.7)
Patients with HAQ DI #0.5 61 (38.1) 62 (39.0) 72 (45.3) 79 (49.7) 151 (47.5) 274 (43.0)
Radiographic results
SHS change from baseline, mean6SD§
At week 208 2.1866.53 1.746 6.71 0.686 3.59 0.546 2.72 0.616 3.19 1.2965.23
At week 256 2.2866.65 1.816 6.82 0.726 3.67 0.606 2.86 0.666 3.30 1.3665.34
SHS change from week 104, mean6SD§
At week 208 0.6863.19 0.796 4.39 0.436 1.82 0.576 2.36 0.506 2.10 0.6263.08
At week 256 0.7863.40 0.876 4.64 0.476 2.05 0.646 2.64 0.556 2.35 0.6963.31
Patients with change in total
SHS #0 at week 256
65 (54.2) 64 (56.6) 75 (62.5) 73 (65.2) 148 (63.8) 277 (59.6)
Patients with change in total
SHS #0.5 at week 256
78 (65.0) 82 (72.6) 92 (76.7) 89 (79.5) 181 (78.0) 341 (73.3)
Estimated annual rate of progression
at baseline, mean6SD
8.44619.37 8.326 27.49 9.756 24.86 6.76614.73 8.316 20.61 8.346 22.14
Estimated annual rate of progression
at week 256, mean6SD
0.4661.34 0.366 1.36 0.146 0.74 0.126 0.57 0.136 0.66 0.2761.07
* Values are the number (percentage) unless indicated otherwise. ITT5 intent-to-treat; MTX5methotrexate; ACR20/50/705American College of
Rheumatology criteria for 20%/50%/70% improvement; DAS28-CRP5Disease Activity Score in 28 joints using the C-reactive protein level;
SDAI5Simplified Disease Activity Index; CDAI5Clinical Disease Activity Index; HAQ5Health Assessment Questionnaire; DI5disability index;
SHS5modified Sharp/van der Heijde score.
† Modified ITT analysis in which the following rules were applied: 1) missing baseline values for continuous variables were replaced with the
median value, and last observation carried forward methodology was applied to missing postbaseline values, and 2) patients who discontinued
study agent due to unsatisfactory therapeutic effect were considered to be nonresponders.
‡ Good or moderate response as defined by the European League Against Rheumatism (14).
§ Includes patients who had an SHS at weeks 0 and 104 and at least 1 score after week 104.
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RESULTS
Data for this report were collected from December 2005 to
June 2012. As previously reported, patient demographics
and disease characteristics at baseline were well-balanced
among the treatment groups (1). A total of 637 patients were
randomly assigned to group 1 (n5 160), group 2 (n5159),
group 3 (n5 159), and group 4 (n5 159; see Supplementary
Table 1, available on the Arthritis Care & Research web
siteat http://onlinelibrary.wiley.com/doi/10.1002/acr.22759/
abstract). Eighty-nine patients (group 1, n5 28; group 2,
n5 22; group 3, n5 20; and group 4, n5 19) met the early
escape criteria at week 28 (4). Through week 104, 140 patients
discontinued the SC study agent, with AEs being the most
common reason (4). A total of 215 patients (33.9%) discontin-
ued the study agent through week 252; 111 (17.5%) discon-
tinued due to an AE, including worsening of RA (n54,
0.6%), and 23 patients (3.6%) discontinued due to unsatis-
factory therapeutic effect (Table 1). A total of 402 patients
(63.4%) completed the safety followup through week 268.
Through week 256, a total of 616 patients received at least
1 administration of golimumab. Of these, 172 received only
the 50-mg dose, 243 received only the 100-mg dose, and 201
received at least 1 administration of each dose during the
trial.
Clinical efficacy and patient-reported outcomes. Clinical
efficacy results from the ITT analysis that included all ran-
domized patients are shown in Table 2. At week 256, 72.8%
of all patients had an ACR20 response, 54.6% had an ACR50
response, and 38.0% had an ACR70 response. After the pla-
cebo crossover at week 52, ACR20 and ACR50 response rates
were maintained for all treatment groups through week 256
(Figure 1). Additionally, 84.1% of all patients had either a
good or moderate DAS28-CRP response at week 256, and
43.3% of patients had a DAS28-CRP ,2.6. Approximately
28% of all patients were in remission at week 256 according
to the SDAI and CDAI remission criteria, and 21.2% met the
Boolean remission criteria (Table 2). Meaningful improve-
ments in physical function were observed, with an overall
mean improvement in HAQ DI score of 0.57 at week 256.
Additionally, at week 256, 72.7% of all patients had an
improvement from baseline$0.25, and 43.0% achieved nor-
mal physical function (HAQ DI #0.5) (Table 2) compared
with 9.1% (58 of 637) who had a normal HAQ DI score at
baseline. The results of the protocol-specified efficacy analy-
sis were consistent with this modified ITT analysis (see Sup-
plementary Table 2, available on the Arthritis Care &
Research web site at http://onlinelibrary.wiley.com/doi/10.
1002/acr.22759/abstract).
A total of 101 patients had an increase in golimumab
dose from 50 mg to 100 mg during the long-term extension
(after week 52), and of these, 100 patients had $12 weeks
of followup available. Among these patients, 84 did not
have a DAS28-CRP ,2.6 immediately prior to dose escala-
tion, and 68 did not have a score#3.2 prior to dose escala-
tion. Both of these subgroups had a mean6SD
improvement in DAS28-CRP of 1.06 1.1 at 12 weeks after
dose escalation.
Improvements from baseline to week 256 in patient-
reported outcomes were generally similar among the treat-
ment groups (Table 3). Mean improvements in SF-36 PCS
and MCS scores ranged from 11.3–11.9 and 4.5–7.6, respec-
tively. Among patients with evaluable SF-36 data at base-
line and week 256, 27.9% had a normal (score $50) SF-36
PCS score, and 46.9% had a normal SF-36 MCS score at
week 256 (Table 3) compared with 1.4% and 28.8% who
had normal baseline SF-36 PCS and MCS scores, respec-
tively. Mean improvements from baseline to week 256 in
the impact of disease on productivity ranged from 3.2–4.3
among the treatment groups.
At week 256, 41.0% (n5261 of 637) of all patients were
receiving concomitant oral corticosteroids (mean dosage:
6.1 mg/day prednisone or equivalent) compared with 52.0%
(n5331 of 637) at baseline (mean dose: 7.4 mg/day). Like-
wise, 67.8% (n5432) used concomitant NSAIDs at week 256
in comparison with 82.9% (n5 528) of patients at baseline.
Radiographic progression. A total of 465 patients (group
1, n5 120; group 2, n5113; group 3, n5 120; and group 4,
n5112) had radiographic data available at baseline, week
104, and at least 1 radiograph after the week-104 time point
and were therefore included in the analysis for reading ses-
sion 3. At week 256, radiographic progression was low, with
a mean change from baseline in SHS for all patients of 1.36;
mean changes among the treatment groups ranged from 0.60
to 2.28 (Table 2). Furthermore, approximately 60% of all
patients had a change in SHS #0 at week 256, and 73% of
patients had a change from baseline#0.5.
At baseline, the mean estimated annual rates of radio-
graphic progression for groups 1, 2, 3, and 4 were 8.44, 8.32,
9.75, and 6.76, respectively (mean duration of RA: group 1,
2.9 years; group 2, 4.1 years; group 3, 3.5 years, and group 4,
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Golimumab 50 mg + MTX
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Figure 1. The proportions of patients with A) American College
of Rheumatology 20% improvement criteria (ACR20) response or
B) ACR50 response through week 256. MTX5methotrexate.
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3.6 years). Over the 5-year study, the mean annual rate of
progression was 0.27 for all patients, and 0.46, 0.36, 0.14,
and 0.12 for groups 1, 2, 3, and 4, respectively.
AEs. A total of 616 patients received at least 1 dose of
golimumab 50 mg or 100 mg and were included in the
safety analysis, and 402 patients completed the safety fol-
lowup through week 268. The mean duration of followup
for all golimumab-treated patients was 205 weeks, and the
mean number of golimumab administrations was 46.9
(Table 4). The most common types of AEs by the Medical
Dictionary for Regulatory Activities classification were
infections and infestations (n5 463, 75.2%), gastrointestinal
disorders (n5323, 52.4%), and musculoskeletal and connec-
tive tissue disorders (n5258, 41.9%). Commonly reported
AEs are listed in Table 4 and include upper respiratory tract
infection (n5181, 29.4%), nausea (n5 121, 19.6%), bronchi-
tis (n5102, 16.6%), and increased alanine aminotransferase
(n5 99, 16.1%). Among all golimumab-treated patients, 73
(11.9%) had at least 1 injection site reaction through week
268; none of these reactions were considered to be severe. Of
the 28,866 golimumab injections administered, 258 (0.9%)
were associated with an injection-site reaction.
Through week 268, 204 patients (33.1%) had at least 1
serious AE. Seventy-five patients (12.2%) had a serious
infection, the most common being pneumonia (n5 14;
2.3%) (Table 4). Among all golimumab-treated patients, the
incidence (95% CI) of serious infections per 100 patient-
years was 4.61 (3.80–5.55). At baseline, 106 patients (16.6%)
required treatment for latent TB. Through week 268, 13
patients were diagnosed with active TB (golimumab 50 mg:
n5 2; 100 mg: n5 11). The majority of these cases were in
endemic countries (e.g., Philippines, Chile, and Thailand).
Ten of these patients had negative tuberculin and Quanti-
FERON testing at screening; the remaining patients were
identified as having latent TB, completed the required treat-
ment as specified in the protocol, and developed active TB
several months after completing the treatment for latent TB.
Eleven TB cases occurred before week 104 and have been
previously described (4). The 2 cases that occurred after
week 104 were TB pleurisy and intestinal TB. There were
no cases of disseminated TB or deaths resulting from TB in
this study. Five opportunistic infections were reported
through week 268. Two were classified as serious infections
(pneumonia legionella, n51; Pneumocystitis jiroveci pneu-
monia, n5 1), and 3 were classified as nonserious infections
(esophageal candidiasis, n5 2; aspergillosis, n51).
Two patients experienced demyelination AEs (demye-
lination of the central nervous system and autoimmune
demyelination); both patients were receiving golimumab
100 mg1MTX. Both AEs were considered to be serious,
and the patients discontinued study treatment. No cases
of systemic lupus erythematosus were reported. Among
all patients who received golimumab, 21 reported a malig-
nancy through week 268. The incidence (95% CI) of all
malignancies per 100 patient-years was 0.87 (0.54–1.33)
(Table 4). Two cases of lymphoma were reported among
golimumab-treated patients (both patients received the
100-mg dose); the incidence (95% CI) per 100 patient-
years for lymphoma was 0.08 (0.01–0.30).
Eight deaths occurred prior to week 104 and have been
previously described (1,4). An additional 4 deaths occurred
after week 104: two patients receiving golimumab 50 mg1
MTX (a 71-year-old woman, with a history of cigarette smok-
ing, died from myocardial infarction, and a 50-year-old
woman, with a history of chronic lung disease, hyperten-
sion, and cigarette smoking, died from unknown causes), 1
patient receiving golimumab 100 mg1placebo (a 68-year-
old woman died from hematemesis), and 1 patient receiving
golimumab 100 mg1MTX (a 61-year-old woman, with a
history of hyperlipidemia, hypertension, and cigarette smok-
ing, died of sepsis). Through week 268, the incidence (95%
CI) of death per 100 patient-years for all golimumab-treated
patients was 0.49 (0.26–0.86).
After discontinuing the study golimumab injections, a
total of 47 patients received a commercial biologic agent
(including commercial golimumab) after week 256. Six of
these patients had an AE after receiving commercial goli-
mumab; most AEs were similar to those reported during
receipt of study drug during the trial. One of these 6
patients had a serious AE (cellulitis).
Golimumab pharmacokinetics and immunogenicity.
Serum trough golimumab concentrations were approximate-
ly dose proportional and were generally maintained through
week 256 for patients who did not have any changes in goli-
Table 3. Improvements in health-related quality of life and productivity at week 256*
Golimumab1MTX
Placebo1
MTX
Golimumab
100 mg1
placebo 50 mg 100 mg Combined Total
SF-36 PCS score
Improvement from baseline, mean6SD 11.36 10.5 11.6611.0 11.96 11.1 11.9610.0 11.96 10.6 11.76 10.7
Patients with score $50, no. (%) 28 (25.7) 28 (26.9) 33 (30.6) 28 (28.3) 61 (29.5) 117 (27.9)
SF-36 MCS score
Improvement from baseline, mean6SD 4.56 12.6 7.6612.0 5.76 12.1 6.46 11.9 6.16 12.0 6.06 12.2
Patients with score $50, no. (%) 47 (43.1) 51 (49.0) 55 (50.9) 44 (44.4) 99 (47.8) 197 (46.9)
Improvement in the impact of disease
on productivity, mean6SD
3.26 3.1 4.364.3 3.96 2.7 4.262.8 4.06 2.8 3.96 3.3
* MTX5methotrexate; SF-365Short Form 36 health survey; PCS5physical component summary; MCS5mental component summary.
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mumab dose. Through week 256, a total of 57 golimumab-
treated patients (9.6%) tested positive for antibodies to goli-
mumab, and of these, 46 patients (92.0%) were positive for
neutralizing antibodies. Eight patients (14.0%) who were
positive for antibodies to golimumab also had an injection
site reaction; 1 reaction of moderate injection site erythema
was classified as serious and led to discontinuation of the
study agent. Among the 538 patients who tested negative for
Table 4. Adverse events through week 268*
50 mg1MTX
only
50 mg and 100 mg
1placebo or MTX
Golimumab
100 mg1placebo
or MTX
Total
golimumab
Treated patients, no. 172 201 243 616
Mean duration of followup, weeks 182.9 238.7 192.7 205.0
Mean number of administrations 41.5 54.9 44.0 46.9
Patients with $1 AE 161 (93.6) 187 (93.0) 234 (96.3) 582 (94.5)
Patients who discontinued due to AEs 30 (17.4) 14 (7.0) 67 (27.6) 111 (18.0)
Common AEs ($10%)
Upper respiratory tract infection 46 (26.7) 72 (35.8) 63 (25.9) 181 (29.4)
Nausea 22 (12.8) 44 (21.9) 55 (22.6) 121 (19.6)
Bronchitis 27 (15.7) 34 (16.9) 41 (16.9) 102 (16.6)
Alanine aminotransferase increased 31 (18.0) 32 (15.9) 36 (14.8) 99 (16.1)
Cough 19 (11.0) 29 (14.4) 37 (15.2) 85 (13.8)
Patients with $1 injection site reaction 15 (8.7) 19 (9.5) 39 (16.0) 73 (11.9)
Patients with $1 SAE 55 (32.0) 55 (27.4) 94 (38.7) 204 (33.1)
Pneumonia 5 (2.9) 5 (2.5) 4 (1.6) 14 (2.3)
Pulmonary tuberculosis 1 (0.6) 1 (0.5) 4 (1.6) 6 (1.0)
Breast cancer 1 (0.6) 0 3 (1.2) 4 (0.6)
Uterine leiomyoma 1 (0.6) 2 (1.0) 1 (0.4) 4 (0.6)
Basal cell carcinoma 0 2 (1.0) 1 (0.4) 3 (0.5)
Hodgkin’s disease 0 0 2 (0.8) 2 (0.3)
Non–small cell lung cancer 2 (1.2) 0 0 2 (0.3)
Patients with $1 serious infection 17 (9.9) 25 (12.4) 33 (13.6) 75 (12.2)
Incidence per 100 patient-years (95% CI) 3.97 (2.54–5.90) 3.68 (2.55–5.15) 6.00 (4.50–7.82) 4.61 (3.80–5.55)
Pneumonia 5 (2.9) 5 (2.5) 4 (1.6) 14 (2.3)
Herpes zoster 0 3 (1.5) 2 (0.8) 5 (0.8)
Pulmonary tuberculosis 1 (0.6) 1 (0.5) 3 (1.2) 5 (0.8)
Sepsis 0 1 (0.5) 3 (1.2) 4 (0.6)
Urinary tract infection 1 (0.6) 2 (1.0) 1 (0.4) 4 (0.6)
Appendicitis 0 2 (1.0) 1 (0.4) 3 (0.5)
Upper respiratory tract infection 1 (0.6) 0 2 (0.8) 3 (0.5)
Malignancies
Lymphoma 0 0 2 (0.8) 2 (0.3)
Incidence per 100 patient-years
(95% CI)
0.00 (0.00–0.50) 0.00 (0.00–0.32) 0.22 (0.03–0.80) 0.08 (0.01–0.30)
SIR (95% CI)† 0.00 (0.00–18.91) 0.00 (0.00–12.15) 9.54 (1.16–34.48) 3.26 (0.39–11.76)
Nonmelanoma skin cancers 0 3 (1.5) 2 (0.8) 5 (0.8)
Incidence per 100 patient-years
(95% CI)
0.00 (0.00–0.50) 0.33 (0.07–0.95) 0.22 (0.03–0.80) 0.21 (0.07–0.48)
Other malignancies 8 (4.7) 2 (1.0) 4 (1.6) 14 (2.3)
Incidence per 100 patient-years
(95% CI)
1.33 (0.57–2.62) 0.22 (0.03–0.78) 0.44 (0.12–1.14) 0.58 (0.32–0.97)
SIR (95% CI)† 2.21 (0.95–4.35) 0.36 (0.04–1.28) 0.85 (0.23–2.18) 1.00 (0.55–1.68)
Total malignancies 8 (4.7) 5 (2.5) 8 (3.3) 21 (3.4)
Incidence per 100 patient-years
(95% CI)
1.33 (0.57–2.62) 0.54 (0.18–1.27) 0.89 (0.38–1.75) 0.87 (0.54–1.33)
SIR (95% CI)† 2.12 (0.91–4.18) 0.34 (0.04–1.23) 1.23 (0.45–2.67) 1.10 (0.63–1.79)
Deaths 6 (3.5) 0 6 (2.5) 12 (1.9)
Incidence per 100 patient-years (95% CI) 0.99 (0.36–2.16) 0.00 (0.00–0.32) 0.67 (0.24–1.45) 0.49 (0.26–0.86)
* Data presented as number (percentage) unless indicated otherwise. MTX5methotrexate; AE5 adverse event; SAE5 serious AE; 95% CI5 95%
confidence interval; SIR5 standardized incidence ratio.
† The SIR is in comparison with the expected number of events in the Surveillance, Epidemiology, and End Results database (2004), which does
not include nonmelanoma skin cancers.
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antibodies to golimumab, 78 (14.5%) had an injection site
reaction; none were serious or led to study discontinuation.
DISCUSSION
The GO-BEFORE trial evaluated the safety and efficacy of
golimumab with and without MTX in MTX-naive patients
with active RA. Through 24 weeks, patients treated with
golimumab 50 mg or 100 mg1MTX had substantial
improvements in disease activity (1), and these improve-
ments were sustained through weeks 52 and 104 (4).
Through 1 year, patients treated with golimumab1MTX
had significantly less radiographic progression than did
patients who received MTX monotherapy (5), and progres-
sion was minimal in all treatment groups at week 104,
when all patients had been receiving golimumab (4). Here
we report the final clinical efficacy, radiographic, and
safety findings through 5 years of the GO-BEFORE trial.
Approximately 66% of patients who were randomized at
baseline continued study treatment through week 252. Long-
term completion rates through 5 years were approximately
46–49% in previous trials of other SC anti-TNF therapies in
patients with RA who were MTX naive (18,19). Among all
randomized patients in the GO-BEFORE trial, 72.8% of
patients had an ACR20 response, 54.6% had an ACR50
response, and 38.0% had an ACR70 response at week 256
(when all patients were receiving golimumab), with no
appreciable differences among the treatment groups. Addi-
tionally, more than 80% of golimumab-treated patients had
either a good or moderate DAS28-CRP response at week 256.
Golimumab-treated patients also had clinically meaningful
improvements in physical function as demonstrated by an
overall mean improvement from baseline in HAQ DI score of
0.57, and by 72.7% of patients having an improvement
$0.25. Radiographic progression was low through 5 years;
the mean change in SHS was 0.72 and 0.60 over 5 years in
patients randomized to golimumab 50 mg1MTX and 100
mg1MTX, respectively, with nearly three-quarters of all
patients having no progression (change in SHS of#0.5).
The proportion of patients using oral corticosteroids
and the median dose received decreased from baseline to
week 256. The proportion of patients using NSAIDs also
decreased during the trial. These observations may sug-
gest that reduced use of these concomitant medications
could be achieved with golimumab treatment. However, it
should be noted that the use of these medications was
solely at the discretion of the investigator.
Safety findings through week 268 were generally consis-
tent with those reported through week 104 (1,4). The majority
of cases of active TB occurred in patients receiving the 100-
mg dose; however, it is difficult to compare the 2 doses (50
and 100 mg) due to the treatment changes allowed through
early escape and adjustments to golimumab and concomitant
medications during the long-term extension. The incidences
of serious infections, lymphoma, and deaths adjusted for
patient-years of exposure for both golimumab doses were
generally consistent with long-term data reported for other
biologic anti-TNF agents from both randomized clinical trials
(18–20) and observational studies (21,22).
Throughout the trial, infections were the most common
type of AE and serious AE; pneumonia was the most com-
mon type of serious infection (n514, 2.3%). There were a
total of 13 cases of active TB. All patients were screened for
TB prior to study entry and had to either have negative TB
test results or initiate treatment for latent TB. The 13 cases
of TB in the GO-BEFORE trial were considered to be new,
active infections and most were in areas with a high back-
ground rate of TB (e.g., Philippines, Chile, and Thailand).
Given the substantial number of patients who were
enrolled from regions with a high TB incidence rate, the
comprehensive screening procedures utilized in this trial
may have contributed to a lower than expected rate of TB
(23). However, physicians should remain vigilant regarding
the development of new TB infections. Five opportunistic
infections were reported, including pneumonia legionella,
P jiroveci pneumonia, and esophageal candidiasis. A total
of 12 deaths occurred through week 268; no predominant
cause of death was identified.
Among golimumab-treated patients, 21 malignancies
were reported. Two cases of lymphoma occurred through
week 268, both in patients receiving golimumab 100 mg,
which corresponded to an SIR (95% CI) of 9.54 (1.16–
34.48). A previous registry analysis of more than 6,000
patients with RA did not show an increase in lymphoma
risk with increasing duration of anti-TNF therapy (24).
Throughout the trial, less than 1% of all golimumab
injections were associated with an injection site reaction.
The incidence of injection site reactions through week 256
was similar between patients who tested positive for anti-
bodies to golimumab (14.0%) and those who tested nega-
tive for antibodies to golimumab (14.5%).
A substantial portion of the patients (66%) who were
enrolled and treated in the GO-BEFORE trial completed
treatment with golimumab through week 252. Interpretation
of the long-term efficacy and safety results is limited by
selection bias over time, although our use of an ITT analysis
including all randomized patients may have mitigated this
effect. The results through 5 years of this study are also lim-
ited by the lack of a control group after week 52, as well as
possible confounding effects of concomitant medications
and golimumab dose changes that were permitted during
the long-term extension. The overall findings of the GO-
BEFORE trial indicate that the majority of patients remained
in the trial through 5 years and had sustained improvements
in clinical and radiographic outcomes with long-term safety
results consistent with other anti-TNF therapies.
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